Clinical Trials Logo

Filter by:
NCT ID: NCT04602416 Completed - Violence, Physical Clinical Trials

Entrepreneurship and Beekeeping in Tanzania

Start date: April 24, 2015
Phase:
Study type: Observational

In Dar es Salaam, Tanzania (DSM) a pre-test post-test intervention pilot study with four arms was conducted. Each arm had 12-15 participants who were young men at risk for violence who were members of one 'camp'. Each participant was interviewed at baseline before the 4 camps were randomized. The interventions were training sessions in: Health (Control), Entrepreneurship, Beekeeping, and All Intervention sessions. Subsequent interviews took place 3 months, 6 months, and 1 year after all the interventions took place. This was a pilot study in preparation for a full intervention trial. The hypotheses for the intervention trial were expected to be that income would increase and violence would decrease in the intervention arms as compared to the Control arm.

NCT ID: NCT04550832 Completed - Clinical trials for Pulmonary Tuberculosis

PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)

DECODE
Start date: October 22, 2021
Phase: Phase 2
Study type: Interventional

This trial is to describe the safety, tolerability and exposure-toxicity relationship of Depazolid given over 16 weeks, in combination with standard-dose Bedaquiline, Delamanid and Moxifloxacin, compared to standard-dose Bedaquiline, Delamanid and Moxifloxacin alone

NCT ID: NCT04517760 Completed - Clinical trials for Pediatric HIV Infection

Evaluating an HIV Risk Screening Tool for Orphans and Vulnerable Children in Tanzania

Start date: February 22, 2018
Phase:
Study type: Observational

The goal of the research was to evaluate the performance of items within the Kizazi Kipya (K2) Orphan and Vulnerable Children (OVC) HIV risk screening tool in identifying HIV-positive children, to optimize an HIV screening tool for OVC and children and adolescents in facility settings and to assess the feasibility and acceptability of home-based HIV risk screening and testing.

NCT ID: NCT04506918 Completed - Clinical trials for Surveys and Questionnaires

Comparison of SMS and IVR Surveys in Tanzania

Start date: October 23, 2020
Phase: N/A
Study type: Interventional

This study focuses on mechanisms to adapt the performance of interactive voice response (IVR) and short message service (SMS) surveys conducted in low-and middle-income (LMIC) setting (Tanzania) and evaluates how the two survey modalities (IVR and SMS) affect survey metrics, including response, completion and attrition rates.

NCT ID: NCT04458077 Completed - Behavior, Child Clinical Trials

Discover Learning - Social, Emotional and Identity Learning for Very Young Adolescents

Start date: August 30, 2020
Phase: N/A
Study type: Interventional

The primary aim of the Discover Learning Project (Discover) is to test an intervention for Very Young Adolescents (VYAs) to promote positive, gender norm transformative, social emotional and identity learning (SEIL). A secondary aim is to better identify effective components of Discover that are scalable requiring the lowest resources to implement

NCT ID: NCT04437836 Completed - Clinical Trial Clinical Trials

Evaluation of Pharmacokinetics and Safety Tolerability of Higher Doses of Rifampic

HighRif C
Start date: July 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Tuberculosis in children is a major public health problem and it contributes 10% of the total TB cases worldwide. TB treatment outcomes in children are challenged by insufficient consideration of the relationships between doses administered, concentrations achieved and eventual desirable and undesirable effects (pharmacodynamics) of TB drugs. Rifampicin is a pivotal TB drug and data from adults suggest that a much higher dose of rifampicin (35 mg/kg instead of 10 mg/kg), resulting in much higher rifampicin exposures in plasma, is safe and tolerable and may provide a higher efficacy. The dose needed in children to achieve the same exposure in plasma is unknown.

NCT ID: NCT04431414 Completed - COVID-19 Clinical Trials

A Study of Immune Responses to the Virus That Causes COVID-19

CoVPN 5001
Start date: July 20, 2020
Phase:
Study type: Observational

The purpose of this study is to learn more about the acute response to infection with and recovery from the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some people know this virus by the name "coronavirus." It can cause the disease called COVID-19. The information gained from the study can be used to help develop better tests for SARS-CoV-2 infection and COVID-19 disease and may help in developing future vaccines, other prevention strategies, and treatments.

NCT ID: NCT04421586 Completed - Vaccination Uptake Clinical Trials

VISTA: Vaccinator-Initiated Screening and TAilored Counseling for Reducing Vaccine Hesitancy

Start date: September 2, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to understand why parents do or do not vaccinate their children and explore what information parents need to vaccinate their children. The study will test whether information about vaccinations provided during pregnancy by a health provider (VISTA intervention) may improve the possibility that a child is vaccinated on time.

NCT ID: NCT04404751 Completed - Anemia Clinical Trials

Quadruple Fortified Salt Clinical Trial

Start date: August 23, 2019
Phase: N/A
Study type: Interventional

Anaemia is the world leading cause of disability and is responsible for about more than 115,000 maternal deaths and 591,000 perinatal deaths per year, of which 3/4 occur in Africa and Asia. Despite the fact that there are several causes of anemia, the most important causes are due to micronutrients deficiency, namely iron, Folic acid and Vitamin B12. Low intakes of these micronutrients consequently affect a woman's health, pregnancy outcome and the nutritional status of breast-fed children. With these in mind we wish to test the effectiveness of salt fortified with these four micronutrients (Iodine, Iron, Folic acid and vitamin B12) in raising the Hemoglobin levels among the non-pregnant and non-lactating women of reproductive age.

NCT ID: NCT04341662 Completed - Clinical trials for Post-Partum Haemorrhage

A Clinical Trial to Study the Effectiveness of a Care Bundle to Prevent Bleeding After a Woman Has Given Birth

E-MOTIVE
Start date: October 13, 2020
Phase: N/A
Study type: Interventional

Every six minutes a mother dies from postpartum haemorrhage (PPH) in low-resource countries, in the prime of her life and often leaving behind a young family. In many settings, when a mother dies in childbirth, her infant has less than a 20% chance of surviving past the first month. PPH, defined as a blood loss of more than 500 ml, is the leading cause of maternal death worldwide, accounting for 27% of maternal deaths. The WHO published "Recommendations for the Prevention and Treatment of Postpartum Hemorrhage" in 2012 to provide evidence-informed recommendations for managing PPH. However, adherence to these recommendations is currently limited by a number of challenges. This primary aim of this multi-country, parallel cluster randomised trial with a baseline control phase, along with mixed-methods and health economic evaluations, is to evaluate the implementation of early detection and the use of the World Health Organisation (WHO) MOTIVE 'first response' treatment bundle for postpartum haemorrhage (PPH) on clinical, implementation and resource use outcomes. The investigators will evaluate the implementation through mixed-methods and carry out a health economic evaluation from the public healthcare system perspective.